Ally Financial Inc vs Amylx Pharmaceuticals Inc — how do they compare? Ally Financial Inc trades at $44.15 (market cap $13.32B), while Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B). The key difference: Ally Financial Inc is far larger — about 5.3× Amylx Pharmaceuticals Inc's market cap, and Ally Financial Inc pays a 2.74% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ALLY | AMLX | |
|---|---|---|
Market Cap | $13.32B | $2.53B |
Sector | Financials | Health |
52-Week High | $47.25 | $24.19 |
52-Week Low | $35.96 | $7.82 |
Dividend Yield | 2.74% | — |
Enterprise Value | — | $2.28B |
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $43.72, down 0.77% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 10.29 and P/B of 0.98, trading below analyst consensus target of $54.40. Recent Q2 2026 earnings missed expectations, causing a 2.4% decline, though revenue grew 10% year-over-year. The company maintains strong institutional support with 68% analyst buy ratings.
Outlook remains cautiously optimistic given the discounted valuation and solid fundamentals, though near-term pressure exists from recent earnings miss and insider selling. Key risks include credit quality concerns, interest rate sensitivity, and competitive pressures in auto lending. The 24% upside to consensus target suggests potential reward for patient investors despite technical weakness.
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
Trailing returns across standard periods
Latest headlines on both assets
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →